Document Detail

Cubicin Outcomes Registry and Experience (CORE) methodology.
MedLine Citation:
PMID:  17904949     Owner:  NLM     Status:  MEDLINE    
The Cubicin Outcomes Registry and Experience (CORE), was designed to retrospectively collect the real-world postmarking experience of patients who received daptomycin. A standardized case report form was used by trained investigators from 45 institutions across the United States. Data on 1,160 patients from November 2003 until December 2004 were collected on demographics, infections, treatments and outcomes at the end of daptomycin therapy. The data from CORE 2004 provide insight into the early clinical use of daptomycin.
Kenneth V I Rolston; John Segreti; Kenneth C Lamp; Lawrence V Friedrich
Related Documents :
17148529 - Identifying, recruiting, and retaining seriously-ill patients and their caregivers in l...
11557329 - Do-not-resuscitate orders - experiences and attitudes of relatives.
20579119 - The prime project: developing a patient evidence-base.
229979 - An example of how patient selection can influence survival in glioblastoma multiforme.
12368559 - Validation of a remote monitoring system for the elderly: application to mobility measu...
12000669 - Dependency as disadvantage - patients' experiences.
15666379 - Noninvasive ventilation for pediatric patients including those under 1-year-old undergo...
20592899 - Predictive capability of anorectal physiologic tests for unfavorable outcomes following...
9482529 - Nursing care of the patient with chronic lymphocytic leukemia.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The American journal of medicine     Volume:  120     ISSN:  1555-7162     ISO Abbreviation:  Am. J. Med.     Publication Date:  2007 Oct 
Date Detail:
Created Date:  2007-10-01     Completed Date:  2007-11-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0267200     Medline TA:  Am J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S4-5     Citation Subset:  AIM; IM    
M. D. Anderson Cancer Center, University of Texas, Houston, Texas, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Bacterial Agents / pharmacology,  therapeutic use*
Daptomycin / pharmacology,  therapeutic use*
Gram-Negative Bacteria / drug effects
Gram-Negative Bacterial Infections / drug therapy
Product Surveillance, Postmarketing*
Skin Diseases, Infectious / drug therapy*
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Anti-Bacterial Agents; 103060-53-3/Daptomycin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Daptomycin in the treatment of patients with infective endocarditis: experience from a registry.
Next Document:  Postmarketing clinical experience in patients with skin and skin-structure infections treated with d...